Market Research Logo

Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Summary


Cancer is a group of diseases that are defined by abnormal cell growth, local tissue invasion and eventual migration to other parts of the body. The diseases are driven by the accumulation of genetic mutations, which provide selective advantages to cells allowing them to evolve and propagate virtually all sites and tissues in the human body.

Cancer currently stands as the second leading cause of death in economically developed countries globally, surpassed only by heart disease (World Health Organization, 2017). Across the eight major developed markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) there were a total of 3.6 Million incident cases of cancer, and 11.2 Million five-year prevalent cases across the top 20 most common sites in 2012. Its prevalence across the globe presents a huge health burden, with over 14 Million new cases being diagnosed in 2012, with a five-year prevalence of 32.6 Million.

Approximately 26 Million new cancer cases and 17 Million cancer deaths per year are projected by 2030 (Ferlay et al., 2015). This increase in cancer incidence and mortality is forecast to be driven by population growth and aging across developed and developing countries, with the global population forecast to reach 8.3 billion by 2030.

The two most common cancers by five-year prevalence are prostate and breast cancers, with 696 and 686 prevalent cases per 500,000 respectively. These have 559,000 and 560,000 incident cases each year, respectively. The other most common cancers comprise a variety of sites across almost all organ systems, with only the CNS and skeletal system not being represented among the top 20 cancers by site.

The report “Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report -

  • Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
  • Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
  • Helps to identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.
Scope
  • The 3,100 products in active development, of which 989 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future cancer immunotherapies market?
  • There are 322 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • Multiple types of cancer immunotherapies exist. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
  • A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?
Reasons to buy
  • Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
  • Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
  • Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking immunotherapeutic approaches to treating cancer indications with current poor prognoses, including melanoma and lung cancer.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
  • Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.


  • Executive Summary
    • A Large Therapy Area with Varying Unmet Needs across Indications
    • A Large Pipeline with a High Degree of First-in- Class Innovation
  • The Case for Innovation in the Oncology Market
    • Table Figure 1: Innovation Trends in Product Approvals, 1987-2013
    • Growing Opportunities for Biologic Products
    • Diversification of Molecular Targets
    • Innovative First-in-Class Product Developments Remain Attractive
      • Table Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
    • Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
    • Sustained Innovation
    • Report Guidance
  • Clinical and Commercial Landscape
    • Therapy Area Overview
      • Epidemiology
        • Table Epidemiology by Top 20 Most Common Cancer Sites, 2012
        • Table Epidemiology by Top 20 Most Common Cancer Sites, Rank 2012
        • Table Epidemiology by Top 20 Most Common Cancer Sites, by age group 2012
        • Table Epidemiology by Top 20 Most Common Cancer Sites, Annual incidence 2012
      • Etiology
      • Pathophysiology
      • Diagnosis
      • Prognosis and Disease Staging
        • Table TNM Staging, 2015
        • Table Figure 3: Relative Survival Rates for the Top 20 Cancers by Site, 2014
        • Table Karnofsky Scores and Equivalent ECOG Staging, 2015
    • Treatment Options
      • Surgery
      • Radiation Therapy
        • Table Optimal and Actual Radiation Therapy Usage Rates in US, 1995-2000
      • Chemotherapy
      • Hormonal Therapies
      • Targeted Therapies
      • Immunotherapies
    • Overview of Marketed Products within Cancer Immunotherapy
      • Table Figure 4: Molecule Types and Molecular Targets of Marketed Products for Oncology, 2017
      • Table Figure 5: Molecule Types and Molecular Targets of Marketed Products within Cancer Immunotherapies, 2017
    • Current Unmet Needs across the Oncology Markets
      • Table Figure 6: Summary of Five-Year Survival Rate, Incidence and Mortality by Site, 2012
  • Assessment of Pipeline Product Innovation
    • Table Figure 7: Pipeline Products by Therapy Area, 2017
    • Cancer Immunotherapies Pipeline by Phase, Molecule Type and Molecular Target
      • Table Figure 8: Cancer Immunotherapies Pipeline Products by Stage of Development and Molecule Type, 2017
      • Table Figure 9: Cancer Immunotherapies Pipeline Products by Stage of Development and Molecular Target, 2017
    • Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family
      • Table Figure 10: Molecular Target Category Comparison, Pipeline and Marketed Products, 2017
    • First-in-Class Pipeline Programs
      • Table Figure 11: Summary of Incidence, Mortality, Mortality Rates and Cancer Immunotherapies Pipeline Activity by Tumor Site, 2015-2017
      • Table Top 10 Cancer Types According to Treatment Demand Criteria, 2017
      • Table Figure 12: Comparison of First-in-Class to Established Products in the Cancer Immunotherapies Pipeline by Tumor Site, 2017
      • First-in-Class Cancer Immunotherapy Products by Phase, Molecule Type and Molecular Target
        • Table Figure 13: Overview of First-In-Class Cancer Immunotherapies Products, 2017
        • Table Figure 14: Percentage Distribution of First-in-Class to Established Products, Cancer Immunotherapies Pipeline, 2017
        • Table Figure 15: Molecular Target Category Comparison, Pipeline First-In-Class and Established Molecular Targets, 2017
        • Table Figure 16: Cancer Immunotherapies, Ratio of First-in-Class Pipeline Targets to First-in-Class Pipeline Products
        • Table Figure 17: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 1
        • Table Figure 18: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 2
        • Table Figure 19: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 3
        • Table Figure 20: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 4
        • Table Figure 21: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 5
        • Table Figure 22: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 6
        • Table Figure 23: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 7
        • Table Figure 24: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 8
        • Table Figure 25: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 9
        • Table Figure 26: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 10
        • Table Figure 27: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 11
        • Table Figure 28: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 12
        • Table Figure 29: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 13
        • Table Figure 30: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 14
        • Table Figure 31: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 15
        • Table Figure 32: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 16
        • Table Figure 33: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 17
        • Table Figure 34: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 18
        • Table Figure 35: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 19
        • Table Figure 36: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 20
        • Table Figure 37: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 21
        • Table Figure 38: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 22
        • Table Figure 39: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 23
        • Table Figure 40: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 24
        • Table Figure 41: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 25
        • Table Figure 42: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 26
        • Table Figure 43: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 27
        • Table Figure 44: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 28
        • Table Figure 45: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 29
        • Table Figure 46: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 30
        • Table Figure 47: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 31
        • Table Figure 48: Cancer Immunotherapies, Global, Pipeline Products, 2017, Part 32
  • Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
    • The Complexity of Signaling Networks in Oncology
    • First-in-Class Molecular Target Integration
    • First-in-Class Target Matrix Assessment
      • Table Figure 49: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 1
      • Table Figure 50: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 2
      • Table Figure 51: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 3
      • Table Figure 52: Cancer Immunotherapies, Global, First-in-Class Molecular Target Analysis Matrix, 2017, Part 4
  • First-in-Class Target Assessment
    • Pipeline Programs that Target Low-Affinity Immunoglobulin Gamma Fc Region Receptor IIIA
      • Table Cancer Immunotherapies, Low-Affinity Immunoglobulin Gamma Gc Region Receptor IIIA as a Therapeutic Target, 2017
      • Table Figure 53: Pipeline Programs Targeting Low-Affinity Immunoglobulin Gamma Fc Region Receptor IIIA
    • Pipeline Programs that Target Programmed Death 1 Ligand-2
      • Table Cancer Immunotherapies, Programmed Cell Death 1
      • Table Figure 54: Pipeline Programs Targeting Programmed Cell Death 1 Ligand 2 (PD-L2)
    • Pipeline Programs that Target OX-2 Membrane Glycoprotein/CD200
      • Table Cancer Immunotherapies, OX-2 Membrane
      • Table Figure 55: Pipeline Programs Targeting OX-2 Membrane Glycoprotein/CD200
    • Pipeline Programs that Target Killer-Cell Immunoglobulin-Like Receptors
      • Table Cancer Immunotherapies, Killer-Cell Immunoglobulin-
      • Table Figure 56: Pipeline Programs Targeting Killer-Cell Immunoglobulin-Like Receptors
    • Pipeline Programs that Target Toll-Like Receptors
      • Table Cancer Immunotherapies, Toll-Like Receptors as a Therapeutic Target, 2017
      • Table Figure 57: Pipeline Programs Targeting Toll-Like Receptor 3
      • Table Figure 58: Pipeline Programs Targeting Toll-Like Receptor 6
      • Table Figure 59: Pipeline Programs Targeting Toll-Like Receptor 8
    • Pipeline Programs that Target Inducible T-Cell Costimulator
      • Table Cancer Immunotherapies, Inducible T-Cell Costimulator as a Therapeutic Target, 2017
      • Table Figure 60: Pipeline Programs Targeting Inducible T-Cell Costimulator
    • Pipeline Programs that Target Membrane Cofactor Protein
      • Table Cancer Immunotherapies, Membrane Cofactor Protein as a Therapeutic Target, 2017
      • Table Figure 61: Pipeline Programs Membrane Cofactor Protein
    • Pipeline Programs that Target NKG2-A/NKG2-B Type II Integral Membrane Protein
      • Table Cancer Immunotherapies, NKG2-A/NKG2-B Type II Integral Membrane Protein as a Therapeutic Target, 2017
      • Table Figure 62: Pipeline Programs Targeting NKG2-A/NKG2-B Type II Integral Membrane Protein
    • Pipeline Programs that Target Stimulator of Interferon Genes Protein
      • Table Cancer Immunotherapies, Stimulator of Interferon Genes Protein as a Therapeutic Target, 2017
      • Table Figure 63: Pipeline Programs Targeting Stimulator of Interferon Genes Protein
    • Conclusion
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Table Figure 64: Cancer Immunotherapies, Global, Licensing Deals by Region and Value, 2006-Q1 2017
      • Table Figure 65: Cancer Immunotherapies, Global, Licensing Deals by Stage and Value, 2006-Q1 2017
      • Table Figure 66: Cancer Immunotherapies, Global, Licensing Deals by Molecule Type, 2006-Q1 2017
      • Table Figure 67: Cancer Immunotherapies, Global, Licensing Deals by Molecular Target, 2006-Q1 2017
      • Table Figure 68: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006-Q1 2017, Part 1
      • Table Figure 69: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006-Q1 2017, Part 2
      • Table Figure 70: Cancer Immunotherapies, Licensing Deals with Disclosed Values, 2006-Q1 2017, Part 3
    • Co-development Deals
      • Table Figure 71: Cancer Immunotherapies, Global, Co-development Deals by Region and Value, 2006-Q1 2017
      • Table Figure 72: Cancer Immunotherapies, Global, Co-development Deals by Stage and Value, 2006-Q1 2017
      • Table Figure 73: Cancer Immunotherapies, Global, Co-development Deals by Molecule Type, 2006-Q1 2017
      • Table Figure 74: Cancer Immunotherapies, Global, Co-development Deals by Molecular Target, 2006-Q1 2017
      • Table Figure 75: Cancer Immunotherapies, Global, Co-development Deals with Disclosed Values, 2006-Q1 2017
      • Table Figure 76: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 1
      • Table Figure 77: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 2
      • Table Figure 78: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 3
      • Table Figure 79: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 4
      • Table Figure 80: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 5
      • Table Figure 81: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 6
      • Table Figure 82: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 7
      • Table Figure 83: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 8
      • Table Figure 84: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 9
      • Table Figure 85: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 10
      • Table Figure 86: Cancer Immunotherapies, Global, First-in-Class Products with No Prior Deal Involvement, 2006-Q1 2017, Part 11
  • Appendix
    • Abbreviations
    • References
    • Research Methodology
      • Data Integrity
      • Innovative and Meaningful Analytical Technique and Frameworks
      • Evidence-based Analysis and Insight
    • Secondary Research
      • Market Analysis
      • Pipeline Analysis
      • First-in-Class Matrix Assessment
      • First-in-Class Target Profiles
      • Licensing and Co-Development Deals
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report